Mga Batayang Estadistika
| CIK | 1514946 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to AXIM Biotechnologies, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 000-54296 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified |
|
| November 13, 2024 |
SEC File Number: 0-54296 CUSIP Number: 05463V 100 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 15, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 9, 2024 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 19, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 AXIM Biotechnologies, Inc. (Exa |
|
| August 13, 2024 |
Clarion Form 12b-25 SEC File Number: 0-54296 CUSIP Number: 05463V 100 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 22, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment #1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 AXIM Biotechn |
|
| May 20, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 AXIM Biotechnologies, Inc. (Ex |
|
| May 15, 2024 |
Clarion Form 12b-25 SEC File Number: 0-54296 CUSIP Number: 05463J 107 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 16, 2024 |
U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended DECEMBER 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission File Number: 000-54296 AXIM BIOTECHNOLOGIES, INC |
|
| April 16, 2024 |
EXHIBIT 4.1 DESCRIPTION OF SECURITIES The following is a summary of the material terms and provisions of the securities of AXIM Biotechnologies, Inc. (“us,” “our,” “we” or the “Company”) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended, and certain provisions of our articles of incorporation (as amended, the “Articles of Incorporation”), and amended and resta |
|
| April 16, 2024 |
Subsidiaries of AXIM Biotechnologies, Inc. EXHIBIT 21.1 Subsidiaries of AXIM Biotechnologies, Inc. 1. Sapphire Biotech, Inc. |
|
| April 1, 2024 |
SEC File Number: 0-54296 CUSIP Number: 05463V 100 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 21, 2024 |
Form of Version 2 Note dated March 15, 2024 CONVERTIBLE PROMISSORY NOTE $[ ] San Diego, California Dated: March 15, 2024 FOR VALUE RECEIVED, the undersigned, Axim Biotechnologies, Inc. |
|
| March 21, 2024 |
Form of Version 3 Note dated March 15, 2024 CONVERTIBLE PROMISSORY NOTE $[ ] San Diego, California Dated: March 15, 2024 FOR VALUE RECEIVED, the undersigned, Axim Biotechnologies, Inc. |
|
| March 21, 2024 |
Form of Stock Purchase Agreement dated March 15, 2024 SECURITIES PURCHASE AGREEMENT This Stock Purchase Agreement (the “Agreement”) is entered into as of March 15, 2024 (the “Effective Date”) by and between [ ] (“Purchaser”), and AXIM Biotechnologies, Inc. |
|
| March 21, 2024 |
Form of Version 1 Note dated March 15, 2024 CONVERTIBLE PROMISSORY NOTE $[ ] San Diego, California Dated: March 15, 2024 FOR VALUE RECEIVED, the undersigned, Axim Biotechnologies, Inc. |
|
| March 21, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 15, 2024 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 21, 2024 |
Form of Convertible Note Purchase Agreement dated March 15, 2024 CONVERTIBLE NOTE PURCHASE AGREEMENT This Convertible Note Purchase Agreement (the “Agreement”) is entered into as of March 15, 2024 (the “Effective Date”) by and between [ ] (“Purchaser”), and AXIM Biotechnologies, Inc. |
|
| February 13, 2024 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 7, 2024 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Commission File Number |
|
| December 28, 2023 |
Convertible Note dated December 26, 2023 EXHIBIT A FORM OF NOTE CONVERTIBLE NOTE $100,000San Diego, CaliforniaDated: December 26, 2023 FOR VALUE RECEIVED, the undersigned, Axim Biotechnologies, Inc. |
|
| December 28, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 26, 2023 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| December 28, 2023 |
Convertible Note Purchase Agreement dated December 26, 2023 CONVERTIBLE NOTE PURCHASE AGREEMENT This Convertible Note Purchase Agreement (this "Agreement') is made and entered into as of December 26, 2023 (the "Effective Date") by and among AXIM Biotechnologies, Inc. |
|
| November 20, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 AXIM Biotechnologies, Inc. |
|
| November 14, 2023 |
Clarion Form 12b-25 SEC File Number: 0-54296 CUSIP Number: 05463V 100 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 21, 2023 |
SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 31, 2023 |
SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 21, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 AXIM Biotechnologies, Inc. (Exa |
|
| August 14, 2023 |
SEC File Number: 0-54296 CUSIP Number: 05463V 100 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 7, 2023 |
AXIM Biotechnologies, Inc. 6191 Cornerstone Court, E. Suite 114 San Diego, CA 92121 AXIM Biotechnologies, Inc. 6191 Cornerstone Court, E. Suite 114 San Diego, CA 92121 June 7, 2023 VIA EDGAR Division of Corporation Finance Office of Life Sciences U.S. Securities & Exchange Commission (the “Commission”) 100 F Street, N.E. Washington, D.C. 20549 Attention: Jimmy McNamara Re: AXIM Biotechnologies, Inc. Registration Statement on Form S-1 Filed June 2, 2023 File No. 333-272390 Ladies |
|
| June 2, 2023 |
Equity Purchase Agreement dated June 1, 2023 Ex. 10.1 EQUITY PURCHASE AGREEMENT This equity purchase agreement is entered into as of June 1, 2023 (this “Agreement”), by and between AXIM Biotechnologies, Inc., a Nevada corporation (the “Company”), and Cross & Company, a Nevada corporation (the “Investor”). WHEREAS, the parties desire that, upon the terms and subject to the conditions contained herein, the Company shall issue and sell to the I |
|
| June 2, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) AXIM Biotechnologies, Inc. |
|
| June 2, 2023 |
As filed with the U.S. Securities and Exchange Commission on June 2, 2023. As filed with the U.S. Securities and Exchange Commission on June 2, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AXIM Biotechnologies, Inc. (Exact name of registrant as specified in its charter) Nevada 2834 27-4029386 (State or Other Jurisdiction of Incorporation) (Primary Stand |
|
| June 2, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 1, 2023 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 30, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 23, 2023 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 30, 2023 |
Form of the Convertible Notes dated May 23, 2023 PROMISSORY NOTE CONVERTIBLE NOTE $ [ ] San Diego, California Dated: May 23, 2023 FOR VALUE RECEIVED, the undersigned, Axim Biotechnologies, Inc. |
|
| May 25, 2023 |
Ex. 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this "Agreement") with an effective date of 23 May 2023 (the "Effective Date"), is made and entered into by and between Accalle, LLC (the "Consultant"), having an office address at 6914 Magellan Way, Sarasota, Florida 34243 and AXIM Biotechnologies, Inc. having an office at 6191 Cornerstone Court, E., Suite 114, San Diego, CA 92121 (the "Com |
|
| May 25, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 23, 2023 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 22, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 AXIM Biotechnologies, Inc. (Ex |
|
| May 15, 2023 |
Clarion Form 12b-25 SEC File Number: 0-54296 CUSIP Number: 05463J 107 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 17, 2023 |
U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended DECEMBER 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission File Number: 000-54296 AXIM Biotechnologies, Inc |
|
| April 17, 2023 |
EXHIBIT 4.1 DESCRIPTION OF SECURITIES The following is a summary of the material terms and provisions of the securities of AXIM Biotechnologies, Inc. (“us,” “our,” “we” or the “Company”) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended, and certain provisions of our articles of incorporation (as amended, the “Articles of Incorporation”), and amended and resta |
|
| April 17, 2023 |
Subsidiaries of AXIM Biotechnologies, Inc. EXHIBIT 21.1 Subsidiaries of AXIM Biotechnologies, Inc. 1. Sapphire Biotech, Inc. |
|
| March 31, 2023 |
Clarion Form 12b-25 SEC File Number: 0-54296 CUSIP Number: 05463V 100 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 27, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 23, 2023 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Commission File Number |
|
| January 27, 2023 |
AGREEMENT, RELEASE AND WAIVER EXHIBIT 10.2 SETTLEMENT AGREEMENT This Settlement Agreement (the “Agreement”) is entered into as of January 23, 2023 (the “Effective Date”) by and between Axim Biotechnologies, Inc. ("AXIM" or the "Company") and John W. Huemoeller II (the "Executive"), with reference to the following facts: RECITALS A.Executive serves and has served as the Chief Executive Officer and |
|
| January 27, 2023 |
TL-66 Convertible Notes Modification and Default Waiver Agreement dated January 23, 2023 Exhibit 10.1 Convertible Notes Modification and Default Waiver Agreement This Convertible Notes Modification and Default Waiver Agreement (the "Agreement") is entered into as of January 23, 2023 (the "Effective Date") by and between TL-66 LLC, a California limited liability company ("Creditor") and Axim Biotechnologies, Inc., a Nevada corporation ("AXIM" or the "Company") and Sapphire Biotechnolog |
|
| January 27, 2023 |
MMI Convertible Note Modification and Default Waiver Agreement dated January 23, 2023 Exhibit 10.3 Convertible Note Modification and Default Waiver Agreement This Convertible Note Modification and Default Waiver Agreement (the "Agreement") is entered into as of January 23, 2023 (the "Effective Date") by and between Medical Marijuana, Inc., an Oregon corporation ("Creditor") and Axim Biotechnologies, Inc., a Nevada corporation ("AXIM" or the "Company"), with reference to the followi |
|
| November 15, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment #1) U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment #1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 AXIM Biot |
|
| November 14, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 AXIM Biotechnologies, Inc. |
|
| September 23, 2022 |
SC 13D 1 aximsc13d.htm SCHEDULE 13D - JUNIPER & IVY CORP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 AXIM Biotechnologies, Inc. (Name of Issuer) Common Stock, par value $.0001 (Title of Class of S |
|
| September 19, 2022 |
Ex. 99.1 AXIM? Biotechnologies Signs Commercialization Agreement With Leading Healthcare Solutions Company for Global Distribution, Sales of Ophthalmic Diagnostics Solutions Company to Sell, Distribute AXIM?s Readers and Three Proprietary Tests Designed for Diagnosis of Dry Eye Disease Globally Through New Agreement SAN DIEGO, September 19, 2022 (GLOBE NEWSWIRE) - AXIM Biotechnologies, Inc. (OTCQB |
|
| September 19, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 15, 2022 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 19, 2022 |
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| August 31, 2022 |
SC 13D/A 1 aximsc13da.htm SCHEDULE 13D/A - CATALINA VALENCIA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1 )1 AXIM Biotechnologies, Inc. (Name of Issuer) Common Stock, par value $.0001 (Title of Clas |
|
| August 31, 2022 |
AXIM / Axim Biotechnologies Inc / Glycodots, LLC - SCHEDULE 13D - GLYCODOTS, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* AXIM Biotechnologies, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05463J 107 (CUSIP Number) John W. Huemoeller II 6191 Cornerstone Court, E., Suite 114 San Diego, CA 92121 (858)923-4422 (Name, Address and Telephone Number of Person A |
|
| August 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* AXIM Biotechnologies, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05463J 107 (CUSIP Number) John W. Huemoeller II 6191 Cornerstone Court, E., Suite 114 San Diego, CA 92121 (858)923-4422 (Name, Address and Telephone Number of Person A |
|
| August 29, 2022 |
Stock Purchase Agreement, dated August 24, 2022 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this ?Agreement?) is made as of the 23rd day of July, 2022 (the ?Effective Date?) by and between AXIM BIOTECHNOLOGIES, INC. |
|
| August 29, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 29, 2022 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 29, 2022 |
Securities Purchase Agreement dated August 24, 2022 Ex. 10.1 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this ?Agreement?) is effective as of the 1st day of August 24, 2022 (the ?Effective Date?) and is made by and between AXIM BIOTECHNOLOGIES, INC., a Nevada corporation (the ?Company?), and Catalina Valencia, (the ?Purchaser?). RECITALS WHEREAS, the Company desires to issue and sell to the Purchaser shares of restricted common stock of |
|
| August 16, 2022 |
NT 10-Q 1 aximnt10q.htm AXIM BIOTECHNOLOGIES, INC. FORM NT 10-Q SEC File Number: 0-54296 CUSIP Number: 05463V 100 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-Q [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR For Period Ended: June 30, 2022 [ ]Transition Report on Form 10-Q [ ]Transit |
|
| August 16, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 AXIM Biotechnologies, Inc. (Exa |
|
| August 2, 2022 |
AXIM Biotechnologies, Inc. 6191 Cornerstone Court, E. Suite 114 San Diego, CA 92121 AXIM Biotechnologies, Inc. 6191 Cornerstone Court, E. Suite 114 San Diego, CA 92121 August 2, 2022 VIA EDGAR Division of Corporation Finance Office of Life Sciences U.S. Securities & Exchange Commission (the ?Commission?) 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: AXIM Biotechnologies, Inc. Registration Statement on Form S-1/A Filed August 2, 2022 File No. 333-266305 La |
|
| August 2, 2022 |
As filed with the U.S. Securities and Exchange Commission on August 2, 2022. As filed with the U.S. Securities and Exchange Commission on August 2, 2022. Registration No. 333-266305 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AXIM Biotechnologies, Inc. (Exact name of registrant as specified in its charter) Nevada 2834 27-4029386 (State or Other Jurisdiction of In |
|
| August 2, 2022 |
EQUITY PURCHASE AGREEMENT This equity purchase agreement is entered into as of July 14, 2022 (this ?Agreement?), by and between AXIM Biotechnologies, Inc. |
|
| July 25, 2022 |
As filed with the U.S. Securities and Exchange Commission on July 22, 2022. As filed with the U.S. Securities and Exchange Commission on July 22, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AXIM Biotechnologies, Inc. (Exact name of registrant as specified in its charter) Nevada 2834 27-4029386 (State or Other Jurisdiction of Incorporation) (Primary Stan |
|
| July 25, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) AXIM Biotechnologies, Inc. |
|
| June 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Axim Biotechnologies, Inc. (Exact name of registrant as specified in its charter) Nevada 27-4029386 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 6191 Cornerstone Court E. Suite 114 San Diego, CA 92121 (Addres |
|
| June 14, 2022 |
Ex. 107 Calculation of Filing Fee Table Form S-8 (Form Type) AXIM BIOTECHNOLOGIES, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Table Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value |
|
| June 14, 2022 |
Form of Stock Award Agreement* Ex. 4.2 AXIM BIOTECHNOLOGIES, INC. STOCK AWARD AGREEMENT UNDER AXIM BIOTECHNOLOGIES, INC. 2015 STOCK INCENTIVE PLAN THIS STOCK AWARD AGREEMENT (the ?Agreement?) is entered into as of , 20 by and between (hereinafter referred to as ?Grantee?) and AXIM Biotechnologies, Inc. a Nevada corporation (hereinafter referred to as the ?Company?), pursuant to the Company?s 2015 Stock Incentive Plan (the ?Plan |
|
| June 14, 2022 |
Amended AXIM Biotechnologies, Inc. 2015 Stock Incentive Plan Ex. 4.1 AXIM BIOTECHNOLOGIES, INC. 2015 STOCK INCENTIVE PLAN Adopted May 20, 2015 THIS AXIM BIOTECHNOLOGIES, INC. 2015 STOCK INCENTIVE PLAN (the ?Plan?) is designed to retain directors, executives and selected employees and consultants and reward them for making contributions to the success of the Company. These objectives are accomplished by making long-term incentive awards under the Plan thereb |
|
| June 14, 2022 |
Form of Stock Option Grant Notice* Ex. 4.3 AXIM BIOTECHNOLOGIES, INC. STOCK OPTION GRANT NOTICE AXIM BIOTECHNOLOGIES, INC. 2015 STOCK INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, AXIM Biotechnologies, Inc. (the ?Company?), hereby grants to the Optionee named below, a stock option (the ?Option?) to purchase any part or all of the specified number of shares of its Common Stock (?Option Shares?), upon the terms and subject to t |
|
| May 23, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 AXIM Biotechnologies, Inc. (Ex |
|
| May 17, 2022 |
SEC File Number: 0-54296 CUSIP Number: 05463V 100 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 19, 2022 |
EXHIBIT 4.1 DESCRIPTION OF SECURITIES The following is a summary of the material terms and provisions of the securities of AXIM Biotechnologies, Inc. (?us,? ?our,? ?we? or the ?Company?) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended, and certain provisions of our articles of incorporation (as amended, the ?Articles of Incorporation?), and amended and resta |
|
| April 19, 2022 |
EXHIBIT 10.7 EXHIBIT B BINDING TERM SHEET This BINDING TERM SHEET (the "Agreement"), dated as of July 29, 2021, is entered into by and between AXIM Biotechnologies Inc., ("AXIM"), a Nevada Corporation, and Advanced Tear Diagnostics, LLC., a Delaware Limited Liability Company ("ATD") . RECITALS A. WHEREAS, ATD is the owner of certain technology and assets related to eye care, including but not limi |
|
| April 19, 2022 |
EXHIBIT 10.8 ASSET PURCHASE AGREEMENT ASSET PURCHASE AGREEMENT (the "Asset Purchase Agreement" or "Agreement") made as of August 26, 2021, by and between and ADVANCED TEAR DIAGNOSTICS, LLC a Delaware Limited Liability Company (the "Seller" or "ATD") and AXIM BIOTECHNOLOGIES, INC., a Delaware corporation, (the "Buyer" or "AXIM"). WITNESSETH: WHEREAS, Seller is the owner of certain eye disease diagn |
|
| April 19, 2022 |
EXHIBIT 10.12 TERMINATION AGREEMENT This Termination Agreement made as of March 3, 2022 (the "Effective Date") by and between AXIM Biotechnologies Inc., a Nevada corporation ("AXIM"), and Empowered Diagnostics LLC, a Florida limited liability Company ("Empowered Diagnostics"), who agree to the following, including the Recitals. RECITALS A. AXIM and Empowered Diagnostics are parties to that certain |
|
| April 19, 2022 |
Subsidiaries of AXIM Biotechnologies, Inc. EXHIBIT 21.1 Subsidiaries of AXIM Biotechnologies, Inc. 1. Sapphire Biotech, Inc. |
|
| April 19, 2022 |
U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment #1) U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment #1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended DECEMBER 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission File Number: 000-54296 AXIM Bio |
|
| April 15, 2022 |
EXHIBIT 10.7 EXHIBIT B BINDING TERM SHEET This BINDING TERM SHEET (the ?Agreement?), dated as of July 29, 2021, is entered into by and between AXIM Biotechnologies Inc., (?AXIM?), a Nevada Corporation, and Advanced Tear Diagnostics, LLC., a Delaware Limited Liability Company (?ATD?) . RECITALS A. WHEREAS, ATD is the owner of certain technology and assets related to eye care, including but not limi |
|
| April 15, 2022 |
U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended DECEMBER 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission File Number: 000-54296 AXIM Biotechnologies, Inc |
|
| April 15, 2022 |
EXHIBIT 10.8 ASSET PURCHASE AGREEMENT ASSET PURCHASE AGREEMENT (the ?Asset Purchase Agreement? or ?Agreement?) made as of August 26, 2021, by and between and ADVANCED TEAR DIAGNOSTICS, LLC a Delaware Limited Liability Company (the ?Seller? or ?ATD?) and AXIM BIOTECHNOLOGIES, INC., a Delaware corporation, (the ?Buyer? or ?AXIM?). WITNESSETH: WHEREAS, Seller is the owner of certain eye disease diagn |
|
| April 15, 2022 |
EXHIBIT 4.1 DESCRIPTION OF SECURITIES The following is a summary of the material terms and provisions of the securities of AXIM Biotechnologies, Inc. (?us,? ?our,? ?we? or the ?Company?) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended, and certain provisions of our articles of incorporation (as amended, the ?Articles of Incorporation?), and amended and resta |
|
| April 15, 2022 |
EXHIBIT 10.12 TERMINATION AGREEMENT This Termination Agreement made as of March 3, 2022 (the ?Effective Date?) by and between AXIM Biotechnologies Inc., a Nevada corporation (?AXIM?), and Empowered Diagnostics LLC, a Florida limited liability Company (?Empowered Diagnostics?), who agree to the following, including the Recitals. RECITALS A. AXIM and Empowered Diagnostics are parties to that certain |
|
| April 15, 2022 |
Subsidiaries of AXIM Biotechnologies, Inc. EXHIBIT 21.1 Subsidiaries of AXIM Biotechnologies, Inc. 1. Sapphire Biotech, Inc. |
|
| March 31, 2022 |
SEC File Number: 0-54296 CUSIP Number: 05463V 100 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 9, 2022 |
AXIM Biotech Launches For Research Use Only Sales for its COVID-19 Neutralizing Antibody Test SAN DIEGO, CA ? March 7, 2022 ? AXIM Biotechnologies, Inc (OTCQB: AXIM) (?AXIM Biotech,? ?AXIM? or ?the Company?), an international healthcare solutions company targeting dry eye disease (DED), today announced that is has shifted its focus for its rapid COVID-19 Neutralizing Antibody (NAb) Test to become For Research Use Only (?RUO?). |
|
| March 9, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 7, 2022 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4029386 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| February 16, 2022 |
THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE ?1933 ACT?) US $1,110,000. |
|
| February 16, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 10, 2022 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 16, 2022 |
Form of 1.5% Short Term Promissory Notes, dated February 10, 2022. PROMISSORY NOTE $250,000 San Diego, California Dated: February 10, 2022 FOR VALUE RECEIVED, the undersigned, Axim Biotechnologies, Inc. |
|
| February 16, 2022 |
Form of 3% Short Term Promissory Notes, dated February 10, 2022. CONVERTIBLE NOTE $[FACE VALUE] San Diego, California Dated: February 10, 2022 FOR VALUE RECEIVED, the undersigned, Axim Biotechnologies, Inc. |
|
| January 12, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 6, 2022 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| January 7, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 4, 2022 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| November 22, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 AXIM Biotechnologies, Inc. |
|
| November 15, 2021 |
SEC File Number: 0-54296 CUSIP Number: 05463V 100 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 23, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 AXIM Biotechnologies, Inc. (Exa |
|
| August 16, 2021 |
SEC File Number: 0-54296 CUSIP Number: 05463V 100 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 4, 2021 |
Exhibit 99.1 AXIM? Biotechnologies to Acquire Technology Including Two FDA-Cleared 510(k)?s for Diagnostic Testing of Dry Eye Disease SAN DIEGO - August 3, 2021 (GLOBE NEWSWIRE) ? AXIM? Biotechnologies, Inc. (OTCQB: AXIM) (?AXIM? Biotech,? ?AXIM? or ?the Company?), a leader in the development of diagnostic testing for COVID-19 and cancer, announced today that the Company has signed a Binding Term |
|
| August 4, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 3, 2021 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 21, 2021 |
AXIM Biotechnologies, Inc. 6191 Cornerstone Court, E. Suite 114 San Diego, CA 92121 AXIM Biotechnologies, Inc. 6191 Cornerstone Court, E. Suite 114 San Diego, CA 92121 June 21, 2021 VIA EDGAR Division of Corporation Finance Office of Life Sciences U.S. Securities & Exchange Commission (the ?Commission?) 100 F Street, N.E. Washington, D.C. 20549 Attention: David Gessert Re: AXIM Biotechnologies, Inc. Registration Statement on Form S-1/A Filed June 9, 2021 File No. 333-256162 Ladie |
|
| June 9, 2021 |
As filed with the U.S. Securities and Exchange Commission on June 9, 2021. As filed with the U.S. Securities and Exchange Commission on June 9, 2021. Registration No. 333-256162 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AXIM Biotechnologies, Inc. (Exact name of registrant as specified in its charter) Nevada 2834 27-4029386 (State or Other Jurisdiction of Incorpo |
|
| June 2, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Amendment #1) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 AXIM Biotec |
|
| May 24, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 AXIM Biotechnologies, Inc. |
|
| May 14, 2021 |
SEC File Number: 0-54296 CUSIP Number: 05463V 100 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 14, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 14, 2021 AXIM Biotechnologies, Inc. (Exact name of Registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 14, 2021 |
EQUITY PURCHASE AGREEMENT This equity purchase agreement is entered into as of May 14, 2021 (this ?Agreement?), by and between AXIM Biotechnologies, Inc. |
|
| May 14, 2021 |
EQUITY PURCHASE AGREEMENT This equity purchase agreement is entered into as of May 14, 2021 (this ?Agreement?), by and between AXIM Biotechnologies, Inc. |
|
| May 14, 2021 |
As filed with the U.S. Securities and Exchange Commission on May 14, 2021. As filed with the U.S. Securities and Exchange Commission on May 14, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AXIM Biotechnologies, Inc. (Exact name of registrant as specified in its charter) Nevada 2834 27-4029386 (State or Other Jurisdiction of Incorporation) (Primary Stand |
|
| April 26, 2021 |
Annual Report - FORM 10-K/A AMENDED ANNUAL REPORT U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Amendment #1 (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM to Commission File Number: 000-54296 AXIM Bio |
|
| April 15, 2021 |
Annual Report - FORM 10-K ANNUAL REPORT U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM to Commission File Number: 000-54296 AXIM Biotechnologies, |
|
| March 30, 2021 |
- FORM 12B-25 NOTICE OF LATE FILING SEC File Number: 0-54296 CUSIP Number: 05463V 100 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 27, 2020 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Amendment No. 1 Form 10-Q/A Amended Quarterly Report U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Amendment No. 1 [X]QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR [ ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm |
|
| November 20, 2020 |
Quarterly Report - FORM 10-Q QUARTERLY REPORT Form 10-Q Quarterly Report U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-5 |
|
| November 13, 2020 |
- FORM 12B-25 NOTICE OF LATE FILING Form 12b-25 Notice of Late Filing SEC File Number: 0-54296 CUSIP Number: 05463J 107 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 18, 2020 |
Quarterly Report - FORM 10-Q/A AMENDED QUARTERLY REPORT Form 10-Q/A Amended Quarterly Report U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Amendment #1) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi |
|
| August 14, 2020 |
Quarterly Report - FORM 10-Q QUARTERLY REPORT Form 10-Q Quarterly Report U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 |
|
| July 24, 2020 |
Form 8K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 21, 2020 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Co |
|
| July 24, 2020 |
Amended and Restated (as of August July 21, 2020) Bylaws of AXIM Biotechnologies, Inc. Exhibit 3.1 Amendment to the Amended and Restated Bylaws of the Company EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF AXIM BIOTECHNOLOGIES, INC. The undersigned hereby certifies that: 1.He is the duly elected, qualified and acting Secretary of AXIM Biotechnologies, Inc., a Nevada corporation (the “Company”), and in charge of the corporate minute book and corporate reco |
|
| July 2, 2020 |
Quarterly Report - FORM 10-Q/A AMENDED QUARTERLY REPORT Form 10-Q/A Amended Quarterly Report U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Amendment #1) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss |
|
| June 30, 2020 |
Quarterly Report - FORM 10-Q QUARTERLY REPORT Form 10-Q Quarterly Report U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X]QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR [ ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 A |
|
| June 30, 2020 |
Form 12b25 Extension SEC File Number: 0-54296 CUSIP Number: 05463J 107 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 29, 2020 |
SAPPHIRE BIOTECH, INC. INDEX TO COMBINED FINANCIAL STATEMENTS Exhibit 99.1 The audited financial statements of Sapphire as of and for the years ended December 31, 2019 and 2018, and the independent auditors’ report related thereto. Exhibit 99.1 SAPPHIRE BIOTECH, INC. INDEX TO COMBINED FINANCIAL STATEMENTS Page Independent Auditors’ Report F-1 Combined Balance Sheets as of December 31, 2019 and 2018 F-2 Combined Statements of Operations for the years ended De |
|
| May 29, 2020 |
Exhibit 99.2 The unaudited pro forma combined consolidated balance sheet as of and for the year ended December 31, 2019, and the pro forma combined statement of operations for the year ended December 31, 2019. Exhibit 99.2 UNAUDITED PRO FORMA COMBINED CONDENSED CONSOLIDATED BALANCE SHEETS OF AXIM BIOTECHNOLOGIES, INC AND SAPPHIRE BIOTECH, INC. AS OF DECEMBER 31, 2019 Axim Biotechnologies, Inc. Sap |
|
| May 29, 2020 |
Financial Statements and Exhibits Form 8-K/A Amended Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 20, 2020 |
Annual Report - FORM 10-K/A ANNUAL REPORT Form 10-K/A Annual Report U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Amendment #1) (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission Fil |
|
| May 14, 2020 |
May 1, 2015, License Agreement with CanChew Biotechnologies, LLC. May 1, 2019, License Agreement with CanChew Biotechnologies, LLC. |
|
| May 14, 2020 |
Form 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 14, 2020 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Co |
|
| May 14, 2020 |
Annual Report - FORM 10-K ANNUAL REPORT Form 10-K Annual Report U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission File Number: 000-542 |
|
| May 13, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events Form 8K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 13, 2020 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Com |
|
| May 13, 2020 |
AXIM® Biotechnologies Issues Update Letter to Shareholders Exhibit 99.1 Press Release Exhibit 99.1 AXIM® Biotechnologies Issues Update Letter to Shareholders SAN DIEGO, May 13, 2020 — AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that it has issued a letter to its shareholders providing commentary on the Com |
|
| May 12, 2020 |
Form 8K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 6, 2020 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Comm |
|
| March 27, 2020 |
Form 8K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 27, 2020 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (C |
|
| March 19, 2020 |
Exhibit 99.1 March 18, 2020, Press Release announcing the Share Exchange Exhibit 99.1 AXIM® Biotechnologies Completes Acquisition of Oncology Research and Development Company Sapphire Biotech, Inc. NEW YORK, March 18, 2020 (GLOBE NEWSWIRE) - AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and |
|
| March 19, 2020 |
Exhibit 10.1 Form of Lock-up Agreement |
|
| March 19, 2020 |
Form 8K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 17, 2020 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (C |
|
| March 19, 2020 |
Exhibit 2.1 Share Exchange Agreement, dated as of March 17, 2020 by and among AXIM Biotechnologies, Inc., Sapphire Biotech, Inc. and its stockholders |
|
| January 8, 2020 |
Exhibit 99.1 Press Release Exhibit 99.1 AXIM® Biotechnologies to Acquire Leading Oncology Research and Development Company Sapphire Biotech, Inc. SAN DIEGO, January 8, 2020 — AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and development, announced today that the Company has signed a binding term sheet to acquire leading |
|
| January 8, 2020 |
Form 8K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 3, 2020 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) ( |
|
| January 8, 2020 |
Exhibit 10.1 Binding Term Sheet dated January 3, 2020, by and between AXIM Biotechnologies, Inc. and Sapphire Industries, Inc |
|
| December 23, 2019 |
AXIM / Axim Biotechnologies, Inc. CORRESP - - SEC Letter December 23, 2019 Kevin Vaugn Rolf Sundwall Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences. |
|
| December 17, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 16, 2019 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) |
|
| December 17, 2019 |
424b5 Prospectus Supplemental Amendment Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| December 17, 2019 |
AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT Exhibit 10.1 Amendment No. 1 to Stock Purchase Agreement, dated December 16, 2019, by and between Axim Biotechnologies, Inc. and Cross & Company AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT THIS AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT (this “Amendment”) is made as of the 16th day of December 2019 (the “Effective Date”) by and between Axim Biotechnologies, Inc., a Nevada corporation (the “Compan |
|
| November 14, 2019 |
AXIM / Axim Biotechnologies, Inc. 10-Q - Quarterly Report - FORM 10-Q QUARTERLY REPORT Form 10-Q Quarterly Report U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-5 |
|
| October 30, 2019 |
Exhibit 10.5 Exclusivity Agreement dated September 3, 2018, by and between Impression Healthcare Limited and AXIM Biotechnologies, Inc. |
|
| October 30, 2019 |
Exhibit 10.7 Supply Agreement dated May 31, 2019, by and between Impression Healthcare Limited and AXIM Biotechnologies, Inc. |
|
| October 30, 2019 |
Exhibit 10.6 Amendment #1 to Exclusivity Agreement dated December 11, 2018, by and between Impression Healthcare Limited and AXIM Biotechnologies, Inc. |
|
| October 30, 2019 |
Exhibit 10.4 Letter of Intent (“Terms Sheet”) dated September 3, 2018, by and between Impression Healthcare Limited and AXIM Biotechnologies, Inc. |
|
| October 30, 2019 |
AXIM / Axim Biotechnologies, Inc. 10-K/A - Annual Report - FORM 10-K/A AMENDED ANNUAL REPORT Form 10-K/A Amended Annual Report U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Amendment #1) (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commis |
|
| October 29, 2019 |
AXIM / Axim Biotechnologies, Inc. CORRESP - - SEC Correspondence October 29, 2019 Kevin Vaugn Rolf Sundwall Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences. |
|
| August 14, 2019 |
AXIM / Axim Biotechnologies, Inc. 10-Q - Quarterly Report - FORM 10-Q QUARTERLY REPORT Form 10-Q Quarterly Report U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 |
|
| July 9, 2019 |
Form 8K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 2, 2019 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Com |
|
| July 9, 2019 |
Exhibit 99.1 Press Release Exhibit 99.1 AXIM® BIOTECHNOLOGIES SIGNS LICENSING AGREEMENT WITH LEADING GUM DISTRIBUTOR TO EXPAND NUTRACEUTICAL DIVISION NEW YORK – July 9, 2019 – AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today announced that the Company has signed a multi-term agreement with KISS |
|
| June 3, 2019 |
Form 8K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 31, 2019 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Com |
|
| June 3, 2019 |
Exhibit 99.1 Press Release Exhibit 99.1 AXIM® Biotechnologies, Inc. Signs Cannabinoid Product Supply Agreement with Healthcare Company for Clinical Trials on Treatment of Periodontitis NEW YORK – June 3, 2019 - AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today announced that it has signed a cann |
|
| May 15, 2019 |
AXIM / Axim Biotechnologies, Inc. 10-Q Quarterly Report FORM 10-Q QUARTERLY REPORT Form 10-Q Quarterly Report U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 |
|
| April 23, 2019 |
Exhibit 99.1 Press Release, dated April 23, 2019 Ex. 99.1 AXIM® Biotechnologies, Inc. Nutraceutical Division Receives Purchase Order for 50,000 Boxes of the Company’s Proprietary CBD-Based Chewing Gum NEW YORK, April 23, 2019 - AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC: AXIM), a world leader in cannabinoid research and development, today announced that the nutrace |
|
| April 23, 2019 |
Form 8K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 19, 2019 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (C |
|
| April 8, 2019 |
AXIM / Axim Biotechnologies, Inc. FORM 10-K ANNUAL REPORT (Annual Report) Form 10-K Annual Report U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission File Number: 000-542 |
|
| April 4, 2019 |
Form 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 2, 2019 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (C |
|
| April 4, 2019 |
AXIM® Biotechnologies, Inc. Appoints Mauricio Javier Gatto-Bellora to Company’s Board of Directors Exhibit 99.1 Press Release AXIM® Biotechnologies, Inc. Appoints Mauricio Javier Gatto-Bellora to Company’s Board of Directors NEW YORK, April 4, 2019 - AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC:AXIM), a world leader in cannabinoid research and development, today announced the appointment of Mauricio Javier Gatto-Bellora to the Company’s Board of Directors. Gatto-B |
|
| March 30, 2019 |
AXIM / Axim Biotechnologies, Inc. FORM NT 10-K NOTICE OF LATE FILING Form NT 10-K Notice of Late Filing SEC File Number: 000-54296 CUSIP Number: 05463V 100 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 26, 2019 |
PREFERRED STOCK PURCHASE AGREEMENT Exhibit 10.1 Preferred Stock Purchase Agreement PREFERRED STOCK PURCHASE AGREEMENT This Preferred Stock Purchase Agreement (the “Agreement”) is entered into as of February 20, 2019 (the “Effective Date”) by and between MJNA Investment Holdings, LLC, a Nevada limited liability company (“Seller”), and Juniper & Ivy Corporation, a Nevada corporation (“Purchaser”), with reference to the following fact |
|
| February 26, 2019 |
Changes in Control of Registrant, Financial Statements and Exhibits Form 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 20, 2019 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation |
|
| January 15, 2019 |
Exhibit 99.2 Press Release AXIM® BIOTECHNOLOGIES LAUNCHES NEW WEBSITE AND MANAGEMENT PRESENTATION TO OUTLINE STRATEGIC BUSINESS INITIATIVES NEW YORK – January 15, 2019 – AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced the launch of a new corporate website and release of its most recent management present |
|
| January 15, 2019 |
Exhibit 99.1 Corporate Slide Presentation |
|
| January 15, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits Form 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 15, 2019 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) |
|
| January 8, 2019 |
AXIM® BIOTECHNOLOGIES APPOINTS NEW CHIEF EXECUTIVE OFFICER Exhibit 99.1 Press Release AXIM® BIOTECHNOLOGIES APPOINTS NEW CHIEF EXECUTIVE OFFICER NEW YORK – January 8, 2019 – AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced the appointment of John W. Huemoeller II as the company’s new Chief Executive Officer (“CEO”). John W. Huemoeller II has served on the Board o |
|
| January 8, 2019 |
Form 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 2, 2019 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) |
|
| December 7, 2018 |
Exhibit 10.1 Securities Purchase Agreement SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of November 28, 2018 is entered into by and between AXIM BIOTECHNOLOGIES, INC., a Nevada corporation (“Company”), and ATLAS SCIENCES, LLC, a Utah limited liability company, its successors and/or assigns (“Investor”). A.Company and Investor are executing and deliv |
|
| December 7, 2018 |
Exhibit 10.3 Debt Exchange Agreement DEBT EXCHANGE AGREEMENT This Debt Exchange Agreement (the “Agreement”) is entered into as of November 28, 2018 (the “Effective Date”) by and between Axim Biotechnologies, Inc., a Nevada corporation (the “Company”), and Atlas Sciences, LLC, a Utah limited liability company (“Atlas”), with reference to the following facts: RECITALS WHEREAS, on June 12, 2017, the |
|
| December 7, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 30, 2018 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation |
|
| December 7, 2018 |
Exhibit 10.2 Convertible Promissory Note CONVERTIBLE PROMISSORY NOTE $4,000,000.00Dated: November 28, 2018 FOR VALUE RECEIVED, the undersigned, Axim Biotechnologies, Inc., a Nevada corporation (“Debtor”), promises to pay to the order of Atlas Sciences, LLC, a Utah limited liability company (“Holder”), at the corporate offices of Holder, or such other place as Holder may designate in writing, the p |
|
| November 14, 2018 |
AXIM / Axim Biotechnologies, Inc. FORM 10-Q QUARTERLY REPORT (Quarterly Report) Form 10-Q Quarterly Report U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X]QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR [ ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-542 |
|
| September 13, 2018 |
Form 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 10, 2018 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporatio |
|
| September 13, 2018 |
Exhibit 99.1 Press Release Exhibit 99.1 AXIM® BIOTECHNOLOGIES SIGNS LOI FOR DISTRIBUTION OF PRODUCTS THROUGHOUT AUSTRALIA AND NEW ZEALAND Leading Cannabinoid Biotech Company Signs Letter of Intent with Leading Australian Healthcare Company for Development of New Products and Assistance with Obtaining Regulatory Approval NEW YORK – September 13, 2018 – AXIM® Biotechnologies, Inc. (AXIM® Biotech) (O |
|
| August 27, 2018 |
Form 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 21, 2018 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) |
|
| August 27, 2018 |
Exhibit 99.1 Press Release Exhibit 99.1 AXIM® BIOTECHNOLOGIES ENTERS CANADIAN MARKET THROUGH NEW EXCLUSIVE DISTRIBUTION AND LICENSE AGREEMENT WITH REVIVE THERAPEUTICS AXIM Partners with REVIVE to Begin Selling Its Leading Cannabidiol-Containing Nutraceutical Product in Canada NEW YORK – Aug. 27, 2018 – AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or the “Company”) (OTC: AXIM), a world leader in ca |
|
| August 17, 2018 |
AXIM / Axim Biotechnologies, Inc. FORM 10-Q/A AMENDED QUARTERLY REPORT (Quarterly Report) Form 10-Q/A Amended Quarterly Report U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 [X]QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR [ ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss |
|
| August 14, 2018 |
AXIM / Axim Biotechnologies, Inc. FORM 10-Q QUARTERLY REPORT (Quarterly Report) Form 10-Q Quarterly Report U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X]QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR [ ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 AX |
|
| May 17, 2018 |
AXIM / Axim Biotechnologies, Inc. FORM 10-Q/A AMENDED QUARTERLY REPORT (Quarterly Report) Form 10-Q/A Amended Quarterly Report U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm |
|
| May 14, 2018 |
AXIM / Axim Biotechnologies, Inc. FORM 10-Q QUARTERLY REPORT (Quarterly Report) Form 10-Q Quarterly Report U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 |
|
| May 11, 2018 |
Entry into a Material Definitive Agreement Current Report on Form 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 7, 2018 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) ( |
|
| April 18, 2018 |
Exhibit 1.1 Stock Purchase Agreement by and between Cross & Company and AXIM Biotechnologies, Inc. dated April 16, 2018. STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of the 16th day of April 2018 (the “Effective Date”) by and between AXIM BIOTECHNOLOGIES, INC., a Nevada corporation (the “Company”), and Cross & Company, a Nevada corporation (the “Purchaser”). |
|
| April 18, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 30, 2018 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (C |
|
| April 18, 2018 |
424b5 PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) PROSPECTUS SUPPLEMENT (To Prospectus Dated September 14, 2017) Registration Statement No. |
|
| April 5, 2018 |
Exhibit 99.1 Press Release Exhibit 99.1 AXIM Biotech Reaches Preliminary Agreement for Distribution of CanChew and MedChew Products Throughout South Korea Press Release | 04/03/2018 NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) - AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTCQB:AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a Memo of Understan |
|
| April 5, 2018 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 15, 2018 |
AXIM / Axim Biotechnologies, Inc. FORM 10-K ANNUAL REPORT (Annual Report) Form 10-K Annual Report U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) [X]ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 [ ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54296 |
|
| November 20, 2017 |
Exhibit 99.3 Audit Committee Charter |
|
| November 20, 2017 |
Compensation Committee Charter. Exhibit 99.2 Compensation Committee Charter |
|
| November 20, 2017 |
Code of Business Conduct and Ethics. Exhibit 14.1 Code of Business Conduct and Ethics |
|
| November 20, 2017 |
AXIM / Axim Biotechnologies, Inc. FORM 10-Q QUARTERLY REPORT (Quarterly Report) Form 10-Q Quarterly Report U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X]QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR [ ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-542 |
|
| November 20, 2017 |
Nominating and Governance Committee Charter. Exhibit 99.1 Nomination Committee Charter |
|
| November 15, 2017 |
AXIM / Axim Biotechnologies, Inc. FORM NT 10-Q NOTICE OF LATE QUARTERLY FILING Form NT 10-Q Notice of Late Quarterly Filing SEC File Number: 0-54296 CUSIP Number: 05463J 107 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 14, 2017 |
AXIM / Axim Biotechnologies, Inc. FORM 10QA AMENDED QUARTERLY REPORT (Quarterly Report) Form 10QA Amended Quarterly Report U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Amendment #1) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| September 14, 2017 |
AXIM / Axim Biotechnologies, Inc. FORM 10-KA AMENDED ANNUAL REPORT (Annual Report) Form 10-KA Amended Annual Report U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Amendment #2) (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss |
|
| September 14, 2017 |
AXIM / Axim Biotechnologies, Inc. FORM 10QA AMENDED QUARTERLY REPORT (Quarterly Report) Form 10QA Amended Quarterly Report U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Amendment #1) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissio |
|
| September 11, 2017 |
AXIM / Axim Biotechnologies, Inc. ESP Acceleration Request Axim Biotechnologies, Inc. 45 Rockefeller Plaza, 20th Floor, Suite 83 New York, NY 10111 (212) 751-0001 September 11, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Axim Biotechnologies, Inc. Registration Statement on Form S-3 File No. 333-220155 (the ?Registration Statement?) REQUEST FOR ACCELERAT |
|
| August 24, 2017 |
Axim Biotechnologies FORM S-3 REGISTRATION STATEMENT Form S-3 Registration Statement SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT Under The Securities Act of 1933 AXIM BIOTECHNOLOGIES, INC. (Exact name of Registrant as specified in its charter) Nevada 2834 27-4029386 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Ide |
|
| August 21, 2017 |
AXIM / Axim Biotechnologies, Inc. FORM 10Q QUARTERLY REPORT (Quarterly Report) Form 10Q Quarterly Report FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 [X]QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR [ ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 AXI |
|
| August 14, 2017 |
Axim Biotechnologies FORM NT 10Q NOTICE OF LATE QUARTERLY FILING Form NT 10Q Notice of Late Quarterly Filing SEC File Number: 0-54296 CUSIP Number: 05463J 107 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 23, 2017 |
Form 8K/A Amended Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 23, 2017 |
Exhibit 10.1 Securities Purchase Agreement |
|
| June 23, 2017 |
Exhibit 10.2 Promissory Note |
|
| June 16, 2017 |
Form 8K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 22, 2017 |
Form 10Q Quarterly Report U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q X .. QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR . TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 A |
|
| May 16, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits Form 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 15, 2017 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Co |
|
| May 16, 2017 |
AXIM BIOTECH CLINICAL STUDY TO DEVELOP BIOEQUIVALENT PRODUCT TO MARINOL LISTED ON CLINICALTRIALS.GOV Exhibit 99.1 Press Release Exhibit 99.1 AXIM BIOTECH CLINICAL STUDY TO DEVELOP BIOEQUIVALENT PRODUCT TO MARINOL LISTED ON CLINICALTRIALS.GOV NEW YORK ? May XX, 2017 ? AXIM? Biotechnologies, Inc. (AXIM? Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, today announced that information on the company?s Bioavailability Study on Dronabinol in a controlled-release, functiona |
|
| May 16, 2017 |
Axim Biotechnologies FORM12B25 NOTICE OF LATE FILING Form12b25 Notice of Late Filing SEC File Number: 0-54296 CUSIP Number: 05463J 107 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 15, 2017 |
Form 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 9, 2017 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (Com |
|
| April 19, 2017 |
U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment #1) Form 10-K/A Amended Annual Report U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment #1) (Mark One) X . ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 . TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commis |
|
| April 17, 2017 |
Axim Biotechnologies FORM 10-K ANNUAL REPORT (Annual Report) Form 10-K Annual Report U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) X . ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 . TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54296 |
|
| March 31, 2017 |
Axim Biotechnologies FORM12B25 NOTICE OF LATE FILING Form12b25 Notice of Late Filing SEC File Number: 0-54296 CUSIP Number: 05463J 107 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 28, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits Form 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 28, 2017 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) ( |
|
| March 28, 2017 |
Exhibit 99.1 Press Release Exhibit 99.1 AXIM BIOTECH ENTERS TERM SHEET AGREEMENT WITH US API COMPANY TO DEVELOP BIOEQUVALENT PRODUCT TO MARINOL NEW YORK ? Mar 28, 2017 AXIM? Biotechnologies, Inc. (AXIM? Biotech) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a Term Sheet Agreement with a U.S.-based controlled-substances API (Active P |
|
| March 22, 2017 |
Axim Biotechnologies FORM 8-K CURRENT REPORT (Current Report/Significant Event) Form 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 21, 2017 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) ( |
|
| March 22, 2017 |
Exhibit 99.1 Press Release Exhibit 99.1 AXIM BIOTECH RETAINS ORA TO MANAGE UPCOMING PRODUCT DEVELOPMENT AND CLINICAL TRIALS ON GLAUCOMA AND DRY EYE INDICATIONS NEW YORK ? March 21, 2017 ? AXIM? Biotechnologies, Inc. (AXIM? Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, today announced that it has retained the services of Ora?, Inc., a global Contract Research Organiz |
|
| March 1, 2017 |
AXIM / Axim Biotechnologies, Inc. / Sanammad Foundation - SCHEDULE 13D/A1 Activist Investment Schedule 13D/A1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1)* Under the Securities Exchange Act of 1934 Axim International, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05463V 100 (CUSIP Number) Phillip E. Koehnke, Esq. P.O. Box 235472 Encinitas, CA 92024 (858) 229-8116 (Name, Address and Te |
|
| March 1, 2017 |
AXIM / Axim Biotechnologies, Inc. / Medical Marijuana Inc - SCHEDULE 13D/A1 Activist Investment Schedule 13D/A1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1)* Under the Securities Exchange Act of 1934 Axim International, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05463V 100 (CUSIP Number) Stuart Titus 12255 Crosthwaite Circle Poway, CA 92064 (844) 710-6562 (Name, Address and Telephone |
|
| January 19, 2017 |
Form 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 18, 2017 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) |
|
| January 10, 2017 |
Axim Biotechnologies FORM 8-K CURRENT REPORT (Current Report/Significant Event) Form 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 20, 2016 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation |
|
| December 30, 2016 |
Axim Biotechnologies FORM 8-K CURRENT REPORT (Current Report/Significant Event) Form 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 20, 2016 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation |
|
| December 13, 2016 |
Axim Biotechnologies FORM 8-K CURRENT REPORT (Current Report/Significant Event) Form 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 7, 2016 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) |
|
| November 30, 2016 |
Form 10-Q/A Amended Quarterly Report FORM 10-Q (Amendment #1) U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 X . QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR . TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi |
|
| November 21, 2016 |
Exhibit 10.1 Employment Contract |
|
| November 21, 2016 |
Exhibit 10.3 Employment Contract |
|
| November 21, 2016 |
Exhibit 10.2 Employment Contract |
|
| November 21, 2016 |
Axim Biotechnologies FORM 10-Q QUARTERLY REPORT (Quarterly Report) Form 10-Q Quarterly Report FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 X . QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR . TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-542 |
|
| November 21, 2016 |
Exhibit 10.4 Convertible Note Purchase Agr |
|
| November 14, 2016 |
Axim Biotechnologies FORM12B25 NOTICE OF LATE FILING Form12b25 Notice of Late Filing SEC File Number: 0-54296 CUSIP Number: 05463J 107 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 25, 2016 |
Form 10-Q/A Amended Quarterly Report FORM 10-Q (Amendment No. 1) U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 X . QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR . TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss |
|
| August 25, 2016 |
Form 10-Q/A Amended Quarterly Report FORM 10-Q (Amendment No. 1) U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 X . QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR . TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss |
|
| August 22, 2016 |
Certificate of Designation of Series C Preferred Stock. Exhibit 3.4 Certificate of Desingation Series C |
|
| August 22, 2016 |
Certificate of Designation of Series B Preferred Stock. Exhibit 3.3 Certificate of Designation Series B |
|
| August 22, 2016 |
Amended and Restated (As of August 17, 2016) Bylaws of AXIM Biotechnologies, Inc. Exhibit 3.2 Amended Bylaws AMENDED AND RESTATED (as of August 17, 2016) BYLAWS OF AXIM BIOTECHNOLOGIES, INC. A Nevada Corporation ARTICLE I OFFICES Section 1. PRINCIPAL OFFICES. The principal office shall be 18 E. 50th Street, 5th Floor, New York, NY 10022. Section 2. OTHER OFFICES. The board of directors may at any time establish branch or subordinate offices at any place or places where the corp |
|
| August 22, 2016 |
Axim Biotechnologies FORM 10-Q QUARTERLY REPORT (Quarterly Report) Form 10-Q Quarterly Report FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 X . QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR . TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 AX |
|
| August 19, 2016 |
Axim Biotechnologies FORM 8-K CURRENT REPORT (Current Report/Significant Event) Form 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 29, 2016 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (C |
|
| August 19, 2016 |
Axim Biotechnologies FORM 8-K CURRENT REPORT (Current Report/Significant Event) Form 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 29, 2016 AXIM BIOTECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Nevada 000-54296 27-4092986 (State or other jurisdiction of incorporation) (C |
|
| August 15, 2016 |
Axim Biotechnologies FORM12B25 NOTICE OF LATE FILING Form12b25 Notice of Late Filing SEC File Number: 0-54296 CUSIP Number: 05463J 107 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 15, 2016 |
Axim Biotechnologies FORM12B25 NOTICE OF LATE FILING Form12b25 Notice of Late Filing SEC File Number: 0-54296 CUSIP Number: 05463J 107 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 26, 2016 |
FORM 10-Q (Amendment #1) U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 AXIM Biotec |
|
| May 23, 2016 |
AXIM Biotechnologies, Inc. 18 E 50th St 5th Floor New York, NY 10022 ex102.htm AXIM Biotechnologies, Inc. 18 E 50th St 5th Floor New York, NY 10022 January 1, 2016 Lekhram Changoer 18 E 50th St 5th Floor New York, NY 10022 Re : AXIM Biotechnologies, Inc. Letter Agreement Dear Lekhram: On behalf of AXIM Biotechnologies, Inc. (the “Company”), we are pleased to confirm your employment in the position of Chief Technology Officer pursuant to the terms and conditions of |
|
| May 23, 2016 |
Axim Biotechnologies FORM 10-Q (Quarterly Report) axom10q.htm FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54296 AXIM Biotechno |
|
| May 13, 2016 |
Axim Biotechnologies FORM 12B-25 noticeoflatefiling.htm SEC File Number: 0-54296 CUSIP Number: 05463J 107 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR For Period Ended: March 31, 2016 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition |
|
| April 18, 2016 |
U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Amendment #1) U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Amendment #1) (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54296 AXIM B |
|
| April 14, 2016 |
Axim Biotechnologies FORM 10-K (12-31-15) (Annual Report) form10k.htm U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54296 AXIM BIOT |
|
| March 30, 2016 |
noticeoflatefiling.htm SEC File Number: 0-54296 CUSIP Number: 05463J 107 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ X ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR For Period Ended: December 31, 2015 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Trans |
|
| February 19, 2016 |
ex991.htm Exhibit 99.1 AXIM Biotech Leads Cannabis Industry in Cannabinoid Research, Development and Intellectual Property; Tackles 15 Debilitating Conditions With No Known Cure Feb 18, 2016 OTC Disclosure & News Service NEW YORK, Feb. 18, 2016 (GLOBE NEWSWIRE) - Dr. George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM? Biotechnologies, Inc. (OTC: AXIM) shares the hemp innovator? |
